X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing National Sickle Cell Awareness Month

By Anne McDonald Pritchett, PhD  |    September 23, 2022
September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities...   Read More

Potential gene therapies bring hope to patients with sickle cell disease

By Katie Koziara  |    June 6, 2022
A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in...   Read More

Gene therapies can reduce treatment burden and costs for patients with blood disorders

By Katie Koziara  |    May 18, 2022
A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...   Read More

Report: More than 500 medicines in development to treat disorders of the blood

By Andrew Powaleny  |    May 18, 2022
Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...   Read More

Report: More than 600 medicines in development for diseases affecting women

By Lori Reilly  |    March 31, 2022
As we approach the end of celebrating Women’s History Month, we’re taking a closer look at the biopharmaceutical progress made and challenges to be addressed for women’s health.   Read More

New Report: Nearly 800 new medicines in development to treat rare diseases

By Andrew Powaleny  |    December 16, 2021
Today, PhRMA released a new report detailing orphan drug development in the U.S. and the potential to meet the significant unmet medical need for patients. Rare diseases and conditions individually...   Read More

Guest post: Continued research and development is critical for ALS patients and families

By Guest Contributor  |    October 25, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

New report shows more than 260 medicines in development to fight neurodegenerative diseases

By Andrew Powaleny  |    October 12, 2021
With neurodegenerative diseases affecting millions of individuals in the United States, now is an important time to spotlight the increasing impact these diseases have on our country’s aging...   Read More

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

By Andrew Powaleny  |    June 22, 2021
We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don’t reach patients, including...   Read More

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

By Andrew Powaleny  |    April 29, 2021
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates